Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CRL
HoldHot AirFLAGCharles River Laboratories International, Inc. · Healthcare · United States · $14.0B · Avg Vol: $247M/d
Insufficient evidence for a screen-pass. Charles River Laboratories International, Inc.: fails the quant gate on quality, value (Q45/V34/M79; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
COMPANY DESCRIPTION
Charles River Laboratories International, Inc. is a leading global contract research organization (CRO), providing a comprehensive suite of preclinical and clinical laboratory services to pharmaceutical, biotechnology, government, and academic clients. The company's competitive moat stems from its integrated service offerings, specialized scientific expertise, global operational scale, and the high switching costs for its clients in critical drug development phases. It serves as an indispensable partner in early-stage drug discovery and development.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.0B | 4.1B | 4.0B | 4.0B | 0.3% | 4.0B | 3.9B | 4.0B | -0.2% |
| EPS | 9.57 | 9.27 | 0.20 | -2.91 | -85.5% | -4.81 | — | — | — |
| Shares | 50.9M | 51.3M | 51.1M | 49.2M | -3.4% | 48.2M | — | — | — |
| Debt | 3.1B | 3.1B | 2.7B | 2.6B | -6.0% | 3.0B | — | — | — |
| Equity | 3.0B | 3.6B | 3.5B | 3.2B | 2.1% | — | — | — | — |
| Op CF | 619.6M | 683.9M | 734.6M | 737.6M | 6.0% | 582.1M | — | — | — |
| Inv CF | -607.9M | -563.2M | -245.1M | -209.3M | — | — | — | — | — |
| Fin CF | -42.4M | -85.5M | -550.9M | -536.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRL | Charles River Laboratories International, Inc.(you) | $14.0B | 63 | Hold |
| RVTY | Revvity, Inc. | $14.4B | 64 | Hold |
| MEDP | Medpace Holdings, Inc. | $16.8B | 80 | Strong Buy |
| WAT | Waters Corporation | $40.7B | 62 | Hold |
| TWST | Twist Bioscience Corporation | $8.9B | 47 | Hold |
| BLLN | BillionToOne, Inc. | $4.4B | 61 | Hold |
| IDXX | IDEXX Laboratories, Inc. | $43.7B | 58 | Hold |
| ILMN | Illumina, Inc. | $32.6B | 75 | Buy |
| GH | Guardant Health, Inc. | $21.7B | 42 | Hold |
| NTRA | Natera, Inc. | $47.0B | 56 | Hold |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%